JeffreyD.HasdayMD
Pulmonology • Baltimore, MDCritical Care Medicine, Pleural Disease
Professor of Medicine, University MD School of Medicine
Dr. Hasday is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-5793Fax+1 410-328-0248
Education & Training
University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 1983 - 1986
Rochester General HospitalResidency, Internal Medicine, 1980 - 1983
University of Rochester School of Medicine and DentistryClass of 1979
Certifications & Licensure
MD State Medical License 1986 - 2026
MI State Medical License 1983 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Top Doctors:Baltimore Area Castle Connolly, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS Start of enrollment: 2018 May 01
Publications & Presentations
PubMed
- First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing p...Mohan E Tulapurkar, Kari Ann Shirey, Katerina Lugkey, Wendy Luo, Ritu Lal
The Journal of Pharmacology and Experimental Therapeutics. 2024-11-22 - First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator with Anti-inflammatory and Endothelial-stabilizing Pr...Mohan E Tulapurkar, Kari Ann Shirey, Katerina N Lugkey, Wendy Luo, Ritu Lal
The Journal of Pharmacology and Experimental Therapeutics. 2024-09-16 - 1 citationsDesign and rationale of the CHILL phase II trial of hypothermia and neuromuscular blockade for acute respiratory distress syndrome.Carl B Shanholtz, Michael L Terrin, Thelma Harrington, Caleb Chan, Whittney Warren
Contemporary Clinical Trials Communications. 2023-06-01
Journal Articles
- Research Paper Transcriptomic Evidence of Immune Activation in Macroscopically Normal-Appearing and Scarred Lung Tissues in Idiopathic Pulmonary FibrosisJeffrey R Galvin, Andrew Clerman, Teri J Franks, Ashutosh Sachdeva, Edward J Britt, Si M Pham, Nevins W Todd, June Kim, Jeffrey D Hasday, Allen P Burke, ScienceDirect
Press Mentions
How Much Should You Care About Inflammation?October 19th, 2023
Grant Support
- Mechanisms Of Fever-Enhanced Acute Lung InjuryNational Heart, Lung, And Blood Institute2008–2011
- The Contribution Of Heat Shock/Stress Pathways To Acute Lung InjuryNational Heart, Lung, And Blood Institute2007–2010
- Mechanisms Of Hsf1-Mediated Repression Of Tnf-AlphaNational Institute Of General Medical Sciences2004–2007
- Mechanisms Of Fever-Enhanced Hyperoxic Lung InjuryNational Heart, Lung, And Blood Institute2003–2006
- Body Temperature And Regulating Host DefensesNational Institute Of Allergy And Infectious Diseases1999–2001
- Receptor-Ligand Events In Macrophage Tumor RecognitionNational Cancer Institute1994
- RECEPTOR: Ligand Events In Macrophage Tumor RecognitionNational Cancer Institute1990–1993
- Receptor--Ligand Events In Macrophage Tumor RecognitionNational Cancer Institute1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
